Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.76 |
| ▸ | USP2 | O75604 | 1/20 | 0.76 |
| ▸ | NPC1 | O15118 | 6/20 | 0.70 |
| ▸ | RAB9A | P51151 | 6/20 | 0.70 |
| ▸ | TP53 | P04637 | 4/20 | 0.70 |
| ▸ | GLA | P06280 | 1/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.59 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.59 |
| ▸ | RELA | Q04206 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | ACR | P10323 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8267163 | 0.92 | SMN1; SMN2 (0.88) | SMN1; SMN2ALDH1A1USP2NPC1RAB9A | |
| SCHEMBL8267293 | 0.87 | SMN1; SMN2 (0.74) | SMN1; SMN2ALDH1A1USP2NPC1RAB9A | |
| SCHEMBL8266868 | 0.86 | RAB9A (0.77) | SMN1; SMN2ALDH1A1USP2NPC1RAB9A | |
| SCHEMBL8267156 | 0.85 | SMN1; SMN2 (0.72) | SMN1; SMN2ALDH1A1USP2NPC1RAB9A | |
| SCHEMBL11534377 | 0.85 | SMN1; SMN2 (0.77) | SMN1; SMN2ALDH1A1USP2NPC1RAB9A | |
| SCHEMBL8267173 | 0.84 | NPC1 (0.90) | SMN1; SMN2ALDH1A1USP2NPC1RAB9A | |
| SCHEMBL2531671 | 0.83 | SMN1; SMN2 (0.74) | SMN1; SMN2ALDH1A1USP2NPC1RAB9A | |
| SCHEMBL21695725 | 0.83 | SMN1; SMN2 (0.69) | SMN1; SMN2ALDH1A1USP2NPC1RAB9A | |
| SCHEMBL21348466 | 0.83 | SMN1; SMN2 (0.73) | SMN1; SMN2ALDH1A1USP2NPC1RAB9A | |
| SCHEMBL10192186 | 0.83 | NPC1 (1.00) | SMN1; SMN2ALDH1A1USP2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10556898-B2 | Indazolyl-1,2,4-thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease | LYCERA CORPORATION (US) | 2020-02-11 | — | — | US | disclosed |
| US-20190276447-A1 | INDAZOLYL-1,2,4-THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | LYCERA CORPORATION | 2019-09-12 | — | — | US | disclosed |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-7973069-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| WO-2007084435-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | SMN1; SMN2 4525/4885ALDH1A1 591/4885USP2 1725/4885 |
| US-20190276447-A1 | INDAZOLYL-1,2,4-THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | ROCK1, ROCK2, TNK2 | SMN1; SMN2 4283/4885ALDH1A1 3126/4885USP2 2260/4885 |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | SMN1; SMN2 3609/4885ALDH1A1 1497/4885USP2 2112/4885 |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | SMN1; SMN2 3609/4885ALDH1A1 1497/4885USP2 2112/4885 |
| US-10556898-B2 | Indazolyl-1,2,4-thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease | ROCK1, ROCK2, TNK2 | SMN1; SMN2 4283/4885ALDH1A1 3126/4885USP2 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.